These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33373715)

  • 1. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
    Etheridge T; Blodi B; Oden N; Van Veldhuisen P; Scott IU; Ip MS; Mititelu M; Domalpally A
    Ophthalmol Retina; 2021 Oct; 5(10):991-998. PubMed ID: 33373715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCORE2 Report 2: Study Design and Baseline Characteristics.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
    Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
    JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SCORE2 Report 24: Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    Ophthalmology; 2023 Oct; 130(10):1066-1072. PubMed ID: 37220815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
    Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
    Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OCT Grading System of Macular Infarction Predicts Vision in Participants With Central Retinal or Hemiretinal Vein Occlusion: A Secondary Analysis of SCORE2.
    Au A; Ip M; Blodi BA; Scott IU; Oden NL; Van Veldhuisen PC; Sarraf D
    Am J Ophthalmol; 2023 Dec; 256():55-62. PubMed ID: 37544495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.
    Ip MS; Oden NL; Scott IU; VanVeldhuisen PC; Blodi BA; Ghuman T; Baker CW;
    JAMA Ophthalmol; 2019 Mar; 137(3):281-287. PubMed ID: 30589922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disorganization of Retinal Inner Layers and Ellipsoid Zone Disruption Predict Visual Outcomes in Central Retinal Vein Occlusion.
    Chan EW; Eldeeb M; Sun V; Thomas D; Omar A; Kapusta MA; Galic IJ; Chen JC
    Ophthalmol Retina; 2019 Jan; 3(1):83-92. PubMed ID: 30929820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion.
    Mimouni M; Segev O; Dori D; Geffen N; Flores V; Segal O
    Am J Ophthalmol; 2017 Oct; 182():160-167. PubMed ID: 28837790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
    Scott IU; Figueroa MJ; Oden NL; Ip MS; Blodi BA; VanVeldhuisen PC;
    Am J Ophthalmol; 2017 Dec; 184():147-156. PubMed ID: 29074161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
    Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
    Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Asia Pac J Ophthalmol (Phila); 2020; 9(1):48-53. PubMed ID: 31990746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
    JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
    Aref AA; Scott IU; VanVeldhuisen PC; King J; Ip MS; Blodi BA; Oden NL;
    JAMA Ophthalmol; 2021 Dec; 139(12):1285-1291. PubMed ID: 34709363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.